PMID- 37564005
OWN - NLM
STAT- MEDLINE
DCOM- 20230828
LR  - 20230830
IS  - 1365-2826 (Electronic)
IS  - 0953-8194 (Linking)
VI  - 35
IP  - 8
DP  - 2023 Aug
TI  - Imaging surveillance in multiple endocrine neoplasia type 1: Ten years of 
      experience with somatostatin receptor positron emission tomography.
PG  - e13322
LID - 10.1111/jne.13322 [doi]
AB  - Guidelines for multiple endocrine neoplasia type 1 (MEN1) recommend intensive 
      imaging surveillance without specifying a superior regimen, including the role of 
      somatostatin receptor imaging (SRI) with positron emission tomography (PET). The 
      primary outcomes were to: (1) Assess change in treatment of duodenal-pancreatic 
      neuroendocrine neoplasms (DP-NENs), bronchopulmonary NENs, and thymic tumors 
      attributed to use of SRI PET/computed tomography (CT) and (2) estimate radiation 
      from imaging and risk of cancer death attributed to imaging radiation. This was a 
      retrospective single center study, including all MEN1 patients, who had had at 
      least one SRI PET/CT. A total of 60 patients, median age 42 (range 21-54) years, 
      median follow-up 6 (range 1-10) years were included. Of 470 cross sectional scans 
      (MRI, CT, SRI PET/CT), 209 were SRI PET/CT. The additional information from SRI 
      PET had implications in 1/14 surgical interventions and 2/12 medical 
      interventions. The estimated median radiation dose per patient was 104 (range 
      51-468) mSv of which PET contributed with 13 (range 5-55) mSv and CT with 91 mSv 
      (range 46-413 mSv), corresponding to an estimated increased median risk of cancer 
      death of 0.5% during 6 years follow-up. SRI PET had a significant impact on 3/26 
      decisions to intervene in 60 MEN1 patients followed for a median of 6 years with 
      SRI PET/CT as the most frequently used modality. The surveillance program showed 
      a high radiation dose. Multi-modality imaging strategies designed to minimize 
      radiation exposure should be considered. Based on our findings, SRI-PET combined 
      with CT cannot be recommended for routine surveillance in MEN1 patients.
CI  - (c) 2023 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons 
      Ltd on behalf of British Society for Neuroendocrinology.
FAU - Said, Maha
AU  - Said M
AUID- ORCID: 0000-0003-0993-8911
AD  - Department of Endocrinology and Metabolism, Copenhagen University Hospital, 
      Rigshospitalet, Copenhagen N, Denmark.
FAU - Krogh, Jesper
AU  - Krogh J
AD  - Department of Endocrinology and Metabolism, Copenhagen University Hospital, 
      Rigshospitalet, Copenhagen N, Denmark.
FAU - Feldt-Rasmussen, Ulla
AU  - Feldt-Rasmussen U
AD  - Department of Endocrinology and Metabolism, Copenhagen University Hospital, 
      Rigshospitalet, Copenhagen N, Denmark.
FAU - Rasmussen, Ase Krogh
AU  - Rasmussen AK
AD  - Department of Endocrinology and Metabolism, Copenhagen University Hospital, 
      Rigshospitalet, Copenhagen N, Denmark.
FAU - Kristensen, Thomas Skaarup
AU  - Kristensen TS
AD  - Department of Radiology, Copenhagen University Hospital, Rigshospitalet, 
      Copenhagen N, Denmark.
FAU - Rossing, Caroline Maria
AU  - Rossing CM
AD  - Department of Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, 
      Copenhagen N, Denmark.
FAU - Johannesen, Helle Hjorth
AU  - Johannesen HH
AD  - Department of Clinical Physiology and Nuclear Medicine, Copenhagen University 
      Hospital, Rigshospitalet, Copenhagen N, Denmark.
FAU - Oturai, Peter
AU  - Oturai P
AD  - Department of Clinical Physiology and Nuclear Medicine, Copenhagen University 
      Hospital, Rigshospitalet, Copenhagen N, Denmark.
FAU - Holmager, Pernille
AU  - Holmager P
AD  - Department of Endocrinology and Metabolism, Copenhagen University Hospital, 
      Rigshospitalet, Copenhagen N, Denmark.
FAU - Kjaer, Andreas
AU  - Kjaer A
AD  - Department of Clinical Physiology and Nuclear Medicine, Copenhagen University 
      Hospital, Rigshospitalet, Copenhagen N, Denmark.
FAU - Klose, Marianne
AU  - Klose M
AD  - Department of Endocrinology and Metabolism, Copenhagen University Hospital, 
      Rigshospitalet, Copenhagen N, Denmark.
FAU - Langer, Seppo
AU  - Langer S
AD  - Department of Oncology, Copenhagen University Hospital, Rigshospitalet, 
      Copenhagen N, Denmark.
FAU - Knigge, Ulrich
AU  - Knigge U
AD  - Department of Endocrinology and Metabolism, Copenhagen University Hospital, 
      Rigshospitalet, Copenhagen N, Denmark.
AD  - Department of surgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen 
      N, Denmark.
FAU - Andreassen, Mikkel
AU  - Andreassen M
AD  - Department of Endocrinology and Metabolism, Copenhagen University Hospital, 
      Rigshospitalet, Copenhagen N, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230811
PL  - United States
TA  - J Neuroendocrinol
JT  - Journal of neuroendocrinology
JID - 8913461
RN  - 0 (Receptors, Somatostatin)
SB  - IM
MH  - Humans
MH  - Young Adult
MH  - Adult
MH  - Middle Aged
MH  - *Positron Emission Tomography Computed Tomography/methods
MH  - Receptors, Somatostatin
MH  - *Multiple Endocrine Neoplasia Type 1/diagnostic imaging
MH  - Retrospective Studies
MH  - Cross-Sectional Studies
MH  - Positron-Emission Tomography/methods
OTO - NOTNLM
OT  - multiple endocrine neoplasia type 1
OT  - neuroendocrine neoplasms
OT  - positron emission tomography
OT  - radiation exposure
OT  - somatostatin receptors
EDAT- 2023/08/11 06:43
MHDA- 2023/08/28 06:42
CRDT- 2023/08/11 03:31
PHST- 2023/06/23 00:00 [revised]
PHST- 2022/10/08 00:00 [received]
PHST- 2023/06/29 00:00 [accepted]
PHST- 2023/08/28 06:42 [medline]
PHST- 2023/08/11 06:43 [pubmed]
PHST- 2023/08/11 03:31 [entrez]
AID - 10.1111/jne.13322 [doi]
PST - ppublish
SO  - J Neuroendocrinol. 2023 Aug;35(8):e13322. doi: 10.1111/jne.13322. Epub 2023 Aug 
      11.